Skip to main content
Clinical Trials/NCT04091698
NCT04091698UnknownPhase 1

11 El-Saraya St. - Manial - Cairo

Cairo University0 sites34 target enrollmentStarted: October 1, 2019Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Enrollment
34
Primary Endpoint
pain score

Study Overview

Brief Summary

The aim of the present investigation is to assess the clinical therapeutic effect of topical use of Coenzyme Q10 versus topical corticosteroid in management of symptomatic oral lichen planus and determine whether the effect, if any, was due to its antioxidant activity.

Detailed Description

Oral lichen planus (OLP) is a relatively common chronic inflammatory mucocutaneous autoimmune disease that primarily affects the skin and mucosal surfaces including the oral cavity with a variety of clinical manifestations including reticular, papular, hyperkeratotic, atrophic, erosive, and bullous forms 1,2. The erosive, atrophic, and bullous type lesions are usually accompanied with pain or burning sensation that affects the patient's quality of life3. Intraorally, the buccal mucosa, dorsum of the tongue and the gingiva are commonly affected 4 .OLP has most often been reported in middle aged patients3. Women account for 60% to 75% of patients with OLP 5.

OLP is estimated to affect1% to 2.0% of the general population. Around 40% of lesions occur on both oral and cutaneous surfaces, 35% occurs on cutaneous surfaces alone, and 25% occur on oral mucosa alone 6,7.

Several predisposing factors might be involved in the pathogenesis of OLP. Earlier studies have implicated stress, anxiety and depression as possible factors. Familial cases of OLP have been reported and the role of genetic predisposition was considered8.

The exact etiology of OLP is still unknown, but cell-mediated immune dysfunction is implicated in the complex etio-pathogenesis of this disease. Large amounts of cytokines that are released by affected keratinocytes and the associated inflammatory elements play a key role in the selective recruitment of cytotoxic CD8+ T cells trigger apoptosis of the basal cells of the oral epithelium. T-cell dominated infiltrate in the sub epithelial region, which characterizes OLP, induces further release of cytokines9.

Cytokines may be produced by nearly every cell, but mostly act locally on cell receptors and have high potency10. Their production gives rise to an inflammatory cascade. One of the most important elements in this cascade is overexpression of tumor necrosis factor-alpha (TNF- α). TNF- α causes tissue destruction and overproduction of other cytokines, especially interleukin (IL)-6 which, in turn, leads to further inflammation and tissue degradation 11. Production of cytokines can in turn stimulate production of Reactive Oxygen Species (ROS) and cause oxidative damage to the tissues 12 .

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

Double-blinded trial, outcome assessors and statistician

Eligibility Criteria

Ages
15 Years to 70 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Patients free from any systemic disease according to the detailed questionnaire of the modified Cornell Medical Index
  • Patients not receiving any medication either topical or systemic that could cause lichenoid reaction during the 3 months before the study.
  • Patients diagnosed by a dermatologist and oral medicine specialist as suffering from OLP.
  • Patients clinically and histopathologically diagnosed as suffering from OLP according to World Health Organization's (WHO's) clinic-pathological diagnostic criteria for LP
  • Patients who agree for the biopsy in undiagnosed cases.
  • Patients who are willing to participate in this study (will give informed consent) and have the ability to complete the study.
  • Exclusion criteria:
  • (1) Patients taking systemic drugs such as systemic steroid, other immunosuppressive therapy for at least 8 weeks prior to the study.
  • (2) Patients treated with any oral topical medications for at least four weeks prior to the study.
  • (3) Patients with suspected restoration-related reaction. (4) Pregnant and lactating mothers.

Exclusion Criteria

  • Not provided

Arms & Interventions

topical Q10 mucoadhesive tablets

Active Comparator

will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.

Intervention: Co-Enzyme Q10 mucoadhesive tablets (Drug)

topical corticosteroid

Placebo Comparator

will receive topical corticosteroid (kenacort A Orabase: triamcinolone acetonide 0.1%5gram adhesive paste - dermapharm), 4 times daily for 3months.

Intervention: Co-Enzyme Q10 mucoadhesive tablets (Drug)

Outcomes

Primary Outcomes

pain score

Time Frame: 3months

visual analogue scale scoring system

clinical size of lesion

Time Frame: 3months

Thongprasom score system

Secondary Outcomes

  • Salivary level of Malondialdehyde(3months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mostafa Abdelsamie Bakry Nafie

demonstrator

Cairo University

Similar Trials

Clinical and Biochemical Assessment of the... | Clinical Trial